Z19.2 — Hormone resistant malignancy status
Is Z19.2 billable?
Yes — Z19.2 is billable for FY2027. Z19.2 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. Z19.2 may be submitted for encounters from October 1, 2026 through September 30, 2027.
Z19.2 at a glance
| Code | Z19.2 |
|---|---|
| Description | Hormone resistant malignancy status |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
What Medicare edits apply to Z19.2?
The Medicare Code Editor screens inpatient claims before they are grouped. These edits name Z19.2 directly.
CMS will reject this code as the principal diagnosis on an inpatient claim. It describes something other than the condition chiefly responsible for the admission.
Which MS-DRGs does Z19.2 group to?
Z19.2 sits in MDC 23 and helps define the logic of 1 MS-DRG (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 951Other Factors Influencing Health Statusmedical
How is Z19.2 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to Z19.2. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Status › malignancy › castrate resistant prostate (post)
- Status › malignancy › hormone resistant (post)
Inclusion terms
Alternative wording in documentation that is classified to Z19.2.
- Castrate resistant prostate malignancy status
Code first — inherited from Z19
The underlying condition below must be sequenced before Z19.2. Z19.2 describes a manifestation and cannot be the principal or first-listed diagnosis.
- malignant neoplasm - see Table of Neoplasms, by site, malignant
How long has Z19.2 existed?
Z19.2 first appears in FY2018 (FY2017 is not available, so it may have appeared then).
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.